Blood Test to Measure DNA Damage in Blood

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00523471
First received: August 30, 2007
Last updated: April 4, 2012
Last verified: April 2012
  Purpose

To check the radiosensitivity level in individual patients based on their DNA damage level.


Condition Intervention
Prostate Cancer
Procedure: Blood test

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Gamma-H2AX as a Molecular Predictor of Prostate Cancer Radiosensitivity

Resource links provided by NLM:


Further study details as provided by AHS Cancer Control Alberta:

Enrollment: 40
Study Start Date: July 2007
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

community sample

Criteria

Inclusion Criteria:

  • prostate cancer diagnosis
  • undergoing radiotherapy
  • agree to participate in study

Exclusion Criteria:

  • not willing to participate
  • not undergoing radiotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00523471

Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Investigators
Principal Investigator: Nadeem Pervez, MBBS, FRCPC AHS Cancer Control Alberta
  More Information

No publications provided

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT00523471     History of Changes
Other Study ID Numbers: GU-6-0076/ethics 23586
Study First Received: August 30, 2007
Last Updated: April 4, 2012
Health Authority: Canada: Health Canada

Keywords provided by AHS Cancer Control Alberta:
prostate cancer
gamma H2AX
radiosensitivity

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on July 29, 2014